Browsing tag:

migraines


migrane

Sumatriptan CAS #: 103628-46-2 Sumatriptan is an API that works with the serotonin neurons in the brain to fight migraines and cluster headaches. By constricting the blood vessels in the brain back to their normal size and preventing the trigeminal nerve from firing at full force, sumatriptan is designed to stop symptoms as soon as they start.[…]

Read More

On January 15, 2015 Pernix Therapeutics excitedly announced an FDA acceptance for a priority review of Sumatriptan and Naproxen Sodium, also known as Treximet, for adolescent patients. Pernix expects an FDA approval by the second quarter of 2015, which would greatly benefit the adolescent patient population suffering from migraines. This anticipated approval would be specific[…]

Read More

On January 5, 2015 Jubilant Life Sciences received an FDA nod for their Rizatriptan generic formulation, paving the way for more generic forms of Merck’s blockbuster migraine medication Maxalt. The strengths approved for generic production are both 5 milligrams and 10 milligrams, which makes up an estimated 70 million dollar market. Rizatriptan is an efficacious[…]

Read More

Exciting news was disseminated from Avanir Pharmaceuticals’ on March 28, 2014 with their announcement that the FDA had accepted a New Drug Application for their intranasal form of Sumatriptan. Designed as a novel and investigational drug-device combination product coined AVP-825, this unique form of Sumatriptan is a breath powered, intranasal form of migraine treatment. The[…]

Read More

Eletriptan Hydrobromide, CAS number 143322-58-1, is a medication indicated for the acute treatment of migraine with or without aura in adults. Known as Relpax, which is marketed by Pfizer, the patent expiration for Eletriptan Hydrobromide is on December 26, 2016 (Patent Use Code U – 876 – TREATMENT OF MIGRAINE WITH OR WITHOUT AURA). Available in[…]

Read More

Topiramate CAS# 97240-79-4, is also known as the brand name medication Topamax. Marketed by Janssen, Topamax has a patent expiration of October 13, 2015. As an effectual and reliable medication to treat patients with both epilepsy and migraines, topiramate is known for it’s effectiveness as monotherapy or adjunctive therapy for the treatment of epilepsy. Tablets[…]

Read More

On November 14th, 2012 Zomig went off-patent, opening the door for generic versions of this formidable product. As an efficacious treatment for patients suffering from migraines with or without auras, zolmitriptan is also known as Zomig, marketed by AstraZeneca. Offered in both oral and orally disintegrating tablets, in 2.5 or 5 milligram tablets, zolmitriptan has[…]

Read More